Ginkgo Bioworks Holdings, Inc. (NYSE:DNA – Get Free Report) was the target of some unusual options trading activity on Monday. Stock traders acquired 10,082 put options on the company. This represents an increase of 533% compared to the typical volume of 1,592 put options.
Ginkgo Bioworks Stock Performance
Shares of DNA stock traded down $1.07 on Monday, reaching $8.54. The stock had a trading volume of 1,612,374 shares, compared to its average volume of 1,536,313. Ginkgo Bioworks has a 1 year low of $5.37 and a 1 year high of $18.22. The stock has a market cap of $574.81 million, a P/E ratio of -2.05 and a beta of 1.74. The company has a 50 day simple moving average of $10.29 and a 200 day simple moving average of $8.64.
Ginkgo Bioworks (NYSE:DNA – Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.64) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.04. The company had revenue of $27.71 million during the quarter, compared to analysts’ expectations of $21.50 million. Ginkgo Bioworks had a negative return on equity of 56.97% and a negative net margin of 249.20%.
Analyst Ratings Changes
DNA has been the subject of several recent analyst reports. BTIG Research restated a “sell” rating and issued a $5.00 price target on shares of Ginkgo Bioworks in a research note on Friday, September 4th. Wall Street Zen raised Ginkgo Bioworks from a “sell” rating to a “hold” rating in a research report on Saturday, September 26th. TD Cowen lifted their price objective on Ginkgo Bioworks from $9.00 to $11.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Oppenheimer set a $5.00 target price on shares of Ginkgo Bioworks in a research note on Wednesday, September 9th. Finally, Zacks Research raised shares of Ginkgo Bioworks to a “hold” rating in a report on Monday, August 17th. Two analysts have rated the stock with a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $7.00.
Check Out Our Latest Report on DNA
Insiders Place Their Bets
In other news, insider Reshma Shetty sold 22,369 shares of the company’s stock in a transaction that occurred on Monday, October 19th. The shares were sold at an average price of $10.14, for a total value of $226,821.66. Following the transaction, the insider owned 453,951 shares in the company, valued at approximately $4,603,063.14. This represents a 4.70% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Steven Coen sold 2,403 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $15.00, for a total transaction of $36,045.00. Following the sale, the insider owned 49,448 shares in the company, valued at approximately $741,720. The trade was a 4.63% decrease in their position. The SEC filing for this sale provides additional information. In the last three months, insiders sold 136,525 shares of company stock valued at $1,379,699. 12.69% of the stock is owned by company insiders.
Hedge Funds Weigh In On Ginkgo Bioworks
A number of institutional investors and hedge funds have recently made changes to their positions in DNA. Balance Capital Partners L.P. bought a new position in shares of Ginkgo Bioworks in the second quarter worth approximately $1,972,179. Caxton Associates LLP increased its stake in shares of Ginkgo Bioworks by 16.7% in the third quarter. Caxton Associates LLP now owns 180,444 shares of the company’s stock worth $2,315,000 after purchasing an additional 25,797 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Ginkgo Bioworks by 23.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 127,048 shares of the company’s stock valued at $779,000 after purchasing an additional 24,434 shares during the period. Bank of New York Mellon Corp raised its position in shares of Ginkgo Bioworks by 1.8% during the 1st quarter. Bank of New York Mellon Corp now owns 123,959 shares of the company’s stock valued at $760,000 after purchasing an additional 2,178 shares during the period. Finally, Renaissance Technologies LLC purchased a new position in shares of Ginkgo Bioworks during the 1st quarter valued at $616,000. Hedge funds and other institutional investors own 78.63% of the company’s stock.
Ginkgo Bioworks Company Profile
Ginkgo Bioworks is a biotechnology company that develops and engineers microorganisms and other cells for use in commercial products. Its platform combines biological research, automation, and software to help customers design, build, and test organisms with desired characteristics. The company provides cell-engineering services and capabilities to organizations in areas including pharmaceuticals, agriculture, food, and industrial chemicals. Its work can include developing and optimizing microbial strains and supporting the production of ingredients and other materials.
Featured Stories
- Five stocks we like better than Ginkgo Bioworks
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
- Embraer’s Record Backlog Looks Promising, But Can It Keep Its Margins Climbing?
Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.
